Pacira BioSciences Reports Second Quarter 2019 Financial Results and Business Update

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Pacira BioSciences Reports Second Quarter 2019 Financial Results and Business Update

Pacira Pharma (PCRX) Tops Q2 EPS by 6c, Revenues Beat; Provides FY19 Sales Outlook

August 8, 2019 8:04 AM EDT

Pacira Pharma (NASDAQ: PCRX) reported Q2 EPS of $0.41, $0.06 better than the analyst estimate of $0.35. Revenue for the quarter came in at $102.6 million versus the consensus estimate of $100.45 million.

Second Quarter 2019 Financial Results

Total revenues were $102.6 million in the second quarter of 2019, a 22 percent increase over the $84.1 million reported for the second quarter of 2018.Total net product sales were $101.8 million in the second quarter of 2019, a 26 percent increase over the $80.7 million reported for the second quarter of 2018.Net product sales of EXPAREL/bupivacaine liposome injectable suspension were $99.8 million in the second... More